Patheon (PTHN) versus Its Competitors Head to Head Comparison

Patheon (NYSE: PTHN) is one of 105 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Patheon to related businesses based on the strength of its profitability, risk, analyst recommendations, dividends, institutional ownership, valuation and earnings.

Insider and Institutional Ownership

0.6% of Patheon shares are held by institutional investors. Comparatively, 44.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 0.1% of Patheon shares are held by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Patheon and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Patheon 0 6 1 0 2.14
Patheon Competitors 885 3844 6831 181 2.54

Patheon presently has a consensus price target of $33.60, indicating a potential downside of 3.95%. As a group, “Pharmaceuticals” companies have a potential upside of 18.77%. Given Patheon’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Patheon has less favorable growth aspects than its rivals.

Valuation & Earnings

This table compares Patheon and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Patheon $1.87 billion $31.70 million 46.03
Patheon Competitors $8.17 billion $1.09 billion 153.88

Patheon’s rivals have higher revenue and earnings than Patheon. Patheon is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Patheon and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Patheon 5.63% -35.93% 4.18%
Patheon Competitors -2,402.45% -68.50% -7.24%

Summary

Patheon rivals beat Patheon on 9 of the 12 factors compared.

Patheon Company Profile

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product’s development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.

What are top analysts saying about Patheon? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Patheon and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit